Current Crohn’s Disease Clinical Trials

Crohn’s Disease

Bristol-Myers Squibb IM133005 – A Phase IIb, Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Dose-Ranging Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with BMS-945429 in Subjects with Moderate to Severe Crohn’s Disease <more info>

Celgene CCT-PDA001-CD-003 – A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the treatment of Crohn’s Disease <more info>

CCFA Pregnancy – A Multi-center National Prospective Study of Pregnancy and Neonatal Outcomes in Women with Inflammatory Bowel Disease Exposed to Immunomodulators and Biologic Therapy <more info>

Elan CD451 – INFORM:  INVESTIGATING NATALIZUMAB THROUGH FURTHER OBSERVATIONAL RESEARCH AND MONITORING <more info>

Millennium C13008 – A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Patients with Ulcerative Colitis and Crohn’s Disease (screening has closed) <more info>

Pfizer A3921083 – A Randomized, Double0Blind, Placebo-Controlled, Parellel Group, Multi-Centre Study to Investigate the Safety and Efficacy of CP-690,550 for Induction Therapy in Subjects with Moderate to Severe Crohn’s Disease <more info>

Pfizer A7281006 – A Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study To Evaluate The Efficacy And Safety Of PF-00547659 In Subjects With Crohn’s Disease <more info>

UCB C87075 – A non-Interventional Long-term Post-Marketing Registry of Patients Treated with Certolizumab Pegol (Cimzia®) for Crohn’s Disease <more info>